fermentek makes and sells biochemicals for research
Fermentek products delivered worldwide by courier
Fermentek homepage
support, sale policy, gmo, mad cow safety, privacy products
contact us
cancer research reagents

Rapamycin (Sirolimus)

MSDSSample CoA
Source: Streptomyces hygroscopicus subsp hygroscopicus
SynonymsRAPA, Rapamune, Sirolimus, RPM, Antibiotic AY 22989
Description: Rapamycin (Sirolimus) is a macrolide compound  that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus (Rapamycin)  is a potent immunosuppressant.  Sirolimus (Rapamycin) possesses both antifungal and antineoplastic properties.
CAS number: 53123-88-9
Merck index: 12, 8288
Molecular weight: 914.2

rapamycin or sale.  - sirolimus structure image free to copy


Molecular Formula: C51H79NO13
Canonical SMILES:  
Methanol, DMSO
Appearance: Off-white to slight yellow powder
Purity: At least 97% by TLC, HPLC
λmax:265, 277, 287
Melting point178°C-182°C
SolubilityRapamycin (Sirolimus) gives clear colorless solution at 50mg/ml DMSO
Storage-20°C. Protect from light and moisture. Hygroscopic.
ApplicationsMedical applications: Rapamycin (Sirolimus) is an immunosuppressant and is used to prevent rejection of kidney and liver transplants. It is also used sometimes in cases of psoriasis, dermatitis.

Research applications: Rapamycin Sirolimus inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Rapamycin Sirolimus inhibits T-lymphocyte activation / proliferation occuring in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressing agents. Sirolimus also inhibits antibody production.

Related products 
 For Research use only. Not for Human or Drug use
GMP/API grade available on request
Rapamycin by Fermentek is not produced from or contains any ingredients from animal origin.
No genetically modified organisms are used.
 Ge L, Iakovou I, Cosgrave J, Chieffo A, Montorfano M, Michev I, Airoldi F, Carlino M, Melzi G, Sangiorgi GM, Corvaja N, Colombo A.
Immediate and mid-term outcomes of Sirolimus (Rapamycin) -eluting stent implantation for chronic total occlusions.
Eur Heart J. 2005 Apr 7
 Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, Emre S.
Sirolimus (Rapamycin)  successfully treats post-transplant autoimmune hepatitis.
Am J Transplant. 2005 May;5(5):1085-9
 Steiner D, Brunicki N, Bachar-Lustig E, Taylor PA, Blazar BR, Reisner Y.
Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin. (Sirolimus)
Exp Hematol. 2006 Jun;34(6):802-8
 Liu Y.
Rapamycin and chronic kidney disease: beyond the inhibition of inflammation.
Kidney Int. 2006 Jun;69(11):1925-7.
 Okuno S.
Mammalian target of rapamycin inhibitors in sarcomas.
Curr Opin Oncol. 2006 Jul;18(4):360-2
 Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S.
Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Oncogene. 2006 May 22
 Aggarwal D, Fernandez ML, Soliman GA.
Rapamycin (Sirolimus), an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs.
Metabolism. 2006 Jun;55(6):794-802
 Jiang X, Yeung RS.
Regulation of Microtubule-Dependent Protein Transport by the TSC2/Mammalian Target of Rapamycin Pathway.
Cancer Res. 2006 May 15;66(10):5258-69
 Marderosian M, Sharma A, Funk AP, Vartanian R, Masri J, Jo OD, Gera JF.
Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.
Oncogene. 2006 May 15
 Smolewski P.
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Anticancer Drugs. 2006 Jun;17(5):487-94
 Webster AC, Lee VW, Chapman JR, Craig JC.
Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
Transplantation. 2006 May 15;81(9):1234-48
 Mercalli A, Sordi V, Ponzoni M, Maffi P, De Taddeo F, Gatti G, Servida P, Bernardi M, Bellio L, Bertuzzi F, Secchi A, Bonifacio E, Piemonti L.
Rapamycin induces a caspase-independent cell death in human monocytes.
Am J Transplant. 2006 Jun;6(6):1331-41
 Kwon YS, Kim JC.
Inhibition of corneal neovascularization by (Sirolimus) rapamycin .
Exp Mol Med. 2006 Apr 30;38(2):173-9

electron-micrograph of streptomyces hygroscopicus, the producer of nigericin

Streptomyces hygroscopicus under electron mycroscope

Rapamycin on Wikipedia




Home Hebrew About  us ISO GMP/API Products Mad cow Sales policy Receiving RFQ Ask scientistContact salesPrivacy  About website 


7AAD17AAG17DMAGA23187 ActinomycinAflatoxin B1Aflatoxin B2Aflatoxin M1AlamethicinAnisomycinApicidinAphidicolinAscomycin
Bafilomycin Brefeldin CastanospermineCeruleninChelerythrineChromomycin A3CitreoviridinCitrininCyclopamineCytochalasin ACytochalasin B
Cytochalasin CCytochalasin DCytochalasin EDihidrocytochalasinDeoxynivalenolDiacetoxyscirpenolFK506ForskolinFumagillinFumonisinGeldanamycin
GliotoxinHypericinHT2 toxinIonomycinK252AK252CKT5720KT5823Leptomycin BMithramycin AMoniliforminMycophenolicMyriocinNigericin
NonactinOchratoxin AOligomycinParthenolidePatulinPaxillinePenicillic acidPenitremPKC412PuromycinPuromycin ANRadicicolStaurosporine
SterigmatocystinT2 toxinTentnoxinThapsigarginThiolutinThiostreptonTriacsinTrichostatinTunicamycinValinomycinVerruculogenVomitoxin
Withaferin WortmanninZearalenone


unique visitor counter
Company's eMail: 

Anti-spam measures have been taken here. Please copy this address into your eMail software. We are sorry for the inconvenience.

Mail Address:
Yatziv 25, Atarot industrial zone,
POB 47120, Jerusalem 97800 Israel
Fax:     972 2 5853943
Phone: 972 2 5853953